Sarepta Therapeutics (SRPT) Insider Trading & Ownership $107.75 -0.66 (-0.61%) As of 11:03 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Sarepta Therapeutics (NASDAQ:SRPT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage7.70%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$4.96 MNumber OfInsiders Selling(Last 12 Months)7Amount OfInsider Selling(Last 12 Months)$13.16 M Get SRPT Insider Trade Alerts Want to know when executives and insiders are buying or selling Sarepta Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address SRPT Insider Buying and Selling by Quarter Sarepta Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/12/2024Hans Lennart Rudolf WigzellDirectorSell10,500$124.84$1,310,820.00 12/5/2024Kathryn Jean BoorDirectorSell1,636$125.55$205,399.80 8/30/2024Ian Michael EstepanCFOSell5,985$137.36$822,099.60 8/16/2024Michael Andrew ChambersDirectorBuy37,038$133.80$4,955,684.40 6/25/2024Ryan Edward BrownEVPSell38,957$161.61$6,295,840.77 6/24/2024Bilal ArifInsiderSell7,859$163.08$1,281,645.72 5/2/2024Dallan MurrayInsiderSell3,635$140.00$508,900.00 3/11/2024Kathryn Jean BoorDirectorSell761$122.93$93,549.73 3/8/2024Hans Lennart Rudolf WigzellDirectorSell15,000$123.25$1,848,750.00 3/5/2024Stephen MayoDirectorSell3,135$122.96$385,479.60 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 3/1/2024Bilal ArifInsiderSell2,000$128.84$257,680.00 3/1/2024Ian Michael EstepanCFOSell1,200$128.30$153,960.00 (Data available from 1/1/2013 forward) SRPT Insider Trading Activity - Frequently Asked Questions Who is on Sarepta Therapeutics's Insider Roster? The list of insiders at Sarepta Therapeutics includes Bilal Arif, Dallan Murray, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Ian Michael Estepan, Kathryn Jean Boor, Michael Andrew Chambers, Richard Barry, Ryan Edward Brown, and Stephen Mayo. Learn more on insiders at SRPT. What percentage of Sarepta Therapeutics stock is owned by insiders? 7.70% of Sarepta Therapeutics stock is owned by insiders. Learn more on SRPT's insider holdings. Which Sarepta Therapeutics insiders have been buying company stock? The following insiders have purchased SRPT shares in the last 24 months: Douglas S Ingram ($2,001,856.00), Michael Andrew Chambers ($9,749,217.58), and Richard Barry ($3,940,500.00). How much insider buying is happening at Sarepta Therapeutics? Insiders have purchased a total of 157,109 SRPT shares in the last 24 months for a total of $15,691,573.58 bought. Which Sarepta Therapeutics insiders have been selling company stock? The following insiders have sold SRPT shares in the last 24 months: Bilal Arif ($1,539,325.72), Dallan Murray ($508,900.00), Hans Lennart Rudolf Wigzell ($4,760,370.00), Ian Michael Estepan ($976,059.60), Kathryn Jean Boor ($298,949.53), Ryan Edward Brown ($6,295,840.77), and Stephen Mayo ($385,479.60). How much insider selling is happening at Sarepta Therapeutics? Insiders have sold a total of 105,668 Sarepta Therapeutics shares in the last 24 months for a total of $14,764,925.22 sold. Sarepta Therapeutics Key ExecutivesMr. Douglas S. Ingram Esq. (Age 61)President, CEO & Director Compensation: $1.62MMr. Ian Michael Estepan (Age 48)Executive VP & CFO Compensation: $917.53k1 recent tradesDr. Louise R. Rodino-Klapac Ph.D. (Age 46)Executive VP, Chief Scientific Officer and Head of Research & Development Compensation: $1.04MMr. Ryan E. Brown J.D. (Age 46)Executive VP, General Counsel & Corporate Secretary Compensation: $823.36kMr. Bilal Arif (Age 52)Executive VP & Chief Technical Operations Officer Ms. Francesca T. NolanExecutive Director of Investor Relations and Corporate CommunicationsMs. Alison NasisiExecutive VP & Chief People OfficerDr. Diane L. Berry Ph.D.Executive VP and Chief of Global Policy & Advocacy OfficerMr. Dallan MurrayExecutive VP & Chief Customer OfficerMr. Will TiltonSenior VP, Head of Strategy & Chief of Staff More Insider Trading Tools from MarketBeat Related Companies argenx Insider Buying BioNTech Insider Buying Teva Pharmaceutical Industries Insider Buying Summit Therapeutics Insider Buying Genmab A/S Insider Buying Intra-Cellular Therapies Insider Buying Viatris Insider Buying Moderna Insider Buying Vaxcyte Insider Buying Roivant Sciences Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying This page (NASDAQ:SRPT) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
